Friday 6 November 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
87.74
1.88
+2.19%
Follow BNTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 3 | 5 |
+8 more TTM periods Free account |
| (8.29%) | (9.53%) | (7.03%) | (6.01%) | ||
| (7.22%) | (8.24%) | (6.26%) | (5.22%) | ||
ROIC |
(34.28%) | (38.39%) | (22.28%) | (19.03%) | |
Return on Tangible Assets |
(10.18%) | (11.87%) | (8.44%) | (7.53%) | |
Average Days of Receivables |
121.76 | 33.00 | 80.73 | 124.23 | |
Free Cash Flow per Share |
(2.10) | 1.98 | 2.22 | (1.35) | |
Free Cash Flow |
(524.10) | 500.72 | 563.49 | (326.41) | |
Capital Expenditures |
(246.89) | (257.85) | (282.16) | (842.33) | |
| Other line items | |||||
Cash ROIC |
(1.39%) | 1.31% | 1.43% | (0.84%) | |
Accounts Receivable Turnover |
3.00 | 3.17 | 3.59 | 2.37 | |
Accounts Payable Turnover |
1.30 | 1.13 | 1.42 | 1.36 | |
Inventory Turnover |
4.09 | 3.95 | 3.70 | 3.36 | |
Average Days of Payables |
317.11 | 367.17 | 277.61 | 304.20 | |
Days of Inventory on Hand |
39.34 | 57.12 | 61.47 | 62.96 | |
Tax Rate |
0.02 | 0.03 | 0.06 | 0.08 | |
Research and Development Expense of Revenue |
100.57% | 84.20% | 77.67% | 73.34% | |
Selling, General and Administrative Expense of Revenue |
31.59% | 27.49% | 23.68% | 21.76% | |
Share Based Compensation of Revenue |
2.54% | 2.66% | 3.02% | 2.82% | |
Interest Coverage |
(57.15) | (40.85) | (32.28) | (20.13) | |
Operating CF/Net income |
0.16 | (0.38) | (0.58) | (0.40) | |
Depreciation/Fixed assets |
0.87 | 0.65 | 0.41 | 0.35 | |
Capex/Depreciation |
(0.25) | (0.33) | (0.53) | (1.94) | |
Revenue per Share |
10.94 | 11.92 | 12.61 | 13.43 | |
Operating CF per Share |
(1.11) | 2.99 | 3.34 | 2.13 | |
Capex per Share |
(0.99) | (1.02) | (1.11) | (3.48) | |
Capex to Sales |
0.09 | 0.09 | 0.09 | 0.26 |
Columns are period end dates · fundamentals updated 5 Nov 2026